Belite Bio (BLTE) Equity Average (2021 - 2025)

Belite Bio has reported Equity Average for 5 years, with the latest figure at $458.2 million in Q4 2025.

• For the quarter ending Q4 2025, Equity Average rose 287.85% year-over-year to $458.2 million; the trailing twelve-month figure through Dec 2025 stood at $458.2 million (up 287.85% YoY), and the FY2025 full-year result was $458.2 million, up 287.85% from the prior year.
• Equity Average for Q4 2025 stood at $458.2 million, up from $118.1 million in the prior quarter.
• The five-year high for Equity Average was $458.2 million in Q4 2025, with the low at -$11.1 million in Q4 2021.
• Average Equity Average over 5 years is $128.9 million, with a median of $66.0 million recorded in 2023.
• Year-over-year, Equity Average jumped 399.59% in 2023 and surged 79.07% in 2024.
• Tracing BLTE's Equity Average over 5 years: stood at -$11.1 million in 2021, then jumped by 219.33% to $13.2 million in 2022, then soared by 399.59% to $66.0 million in 2023, then surged by 79.07% to $118.1 million in 2024, then soared by 287.85% to $458.2 million in 2025.
• The last three Equity Average figures came in at $458.2 million (Q4 2025), $118.1 million (Q4 2024), and $66.0 million (Q4 2023), per Business Quant data.

Peer Comparison